Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05

Alicja Joanna Urbaniak

Instructor

Also affiliated: University of Arkansas Medical Center (2021); Adam Mickiewicz University in Poznań (2012–2017)

15 h-index 61 pubs 613 cited

  • Humans
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • Cell Survival
  • Apoptosis
  • Polyether Polyketides
  • Pyrans
  • Colchicine
  • Molecular Docking Simulation
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Female
  • Neoplasms
  • Tubulin Modulators

Biography and Research Information

OverviewAI-generated summary

Alicja Joanna Urbaniak's research investigates the biological activity of modified compounds, with a focus on their potential as anticancer agents. Her work includes the synthesis and in vitro evaluation of new amides derived from colchicine, specifically targeting cancer cells. Urbaniak also studies the antitumor properties of natural compounds and their derivatives, such as salinomycin analogs and components found in Trametes versicolor (Turkey tail mushroom), demonstrating anti-melanoma activity. Her research explores both synthetic modifications of known bioactive molecules and the assessment of natural products for therapeutic applications. She has published 62 papers, accumulating 617 citations, and holds an h-index of 15. Key collaborators at the University of Arkansas for Medical Sciences include Angus M. MacNicol, Steven R. Post, Billie Heflin, and Timothy C. Chambers.

Metrics

  • h-index: 15
  • Publications: 61
  • Citations: 613

Positions

  • Instructor 2020–present
    University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
  • Post Doctoral Fellow 2017–2020
    University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
  • Research Technician 2016–2017
    University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID

Selected Publications

  • Repurposing Monensin and Its Derivatives as Immune-Modulatory Candidates for Metastatic Breast Cancer (Abstract ID: 231537) (2026)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
  • Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)
    Journal for ImmunoTherapy of Cancer DOI OpenAlex
  • Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)
    ACS Pharmacology & Translational Science 1 citation DOI OpenAlex
  • Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
    Frontiers in Immunology 1 citation DOI OpenAlex
  • Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
    bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
  • Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)
    Cancer Research DOI OpenAlex
  • Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
  • 474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025)
    Journal of Clinical and Translational Science DOI OpenAlex
  • Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)
    Biomedicines 6 citations DOI OpenAlex
  • Monensin and its derivatives increase MHC Class I and II presentations in breast cancer (2024)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
  • 383 Beyond Antibiotics: Monensin and its Derivatives as Promising Anti-Breast Cancer Agents (2024)
    Journal of Clinical and Translational Science DOI OpenAlex
  • Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)
    Chemistry & Biodiversity 1 citation DOI OpenAlex
  • Experimental pharmacology in precision medicine (2023)
    Pharmacology Research & Perspectives 6 citations DOI OpenAlex
  • Musashi Exerts Control of Gonadotrope Target mRNA Translation During the Mouse Estrous Cycle (2023)
    Endocrinology 11 citations DOI OpenAlex
  • Monensin and its Derivatives Exhibit Anti-Melanoma Activity In Vitro (2023)
    Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

149 Collaborators 44 Institutions 10 Countries

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics